LivaNova PLC, a global medical technology company with its headquarters in London, has confirmed the election of Jette Nygaard-Andersen to its Board of Directors. The announcement came after the company's Annual General Meeting of shareholders on June 10, where her appointment received approval. Ms Nygaard-Andersen is recognised for her substantial leadership background in highly regulated international sectors.
William Kozy, Chair of LivaNova, expressed satisfaction with the new addition, highlighting Ms Nygaard-Andersen's expertise in medtech governance, her track record as a CEO, and her experience in business transformation, strategic mergers and acquisitions, and digital innovation across complex global operations. Her international perspective and public company board experience are expected to be valuable assets to LivaNova, which operates in over 100 countries and employs approximately 3,300 people.
Ms Nygaard-Andersen currently serves as Chair of the Board for Coloplast A/S, a Danish global medical device company, where she has been a Non-Executive Director since 2015. Her previous roles include Chief Executive Officer and Executive Director of Entain plc, a global sports betting and gaming firm, where she spearheaded a significant business transformation. Prior to Entain, she spent 16 years at Modern Times Group AB, a European media and entertainment group, holding various senior executive positions.
Concurrent with Ms Nygaard-Andersen's arrival, Dr. Sharon O’Kane has retired from the Board, having chosen not to seek re-election after a decade of service. Mr Kozy extended the company's gratitude to Dr O’Kane for her contributions, particularly her leadership as Chair of the Nominating and Corporate Governance Committee since 2017 and her tenure as Lead Independent Director. Her insights have been instrumental in guiding LivaNova through key developmental stages.
Following Dr O’Kane's departure, several other board committee changes have been implemented. Brooke Story, who joined the Board in 2022, will succeed Dr O’Kane as Chair of the Nominating and Corporate Governance Committee. Peter Wilver will take over as Chair of the Compensation and Human Capital Management Committee from Stacy Enxing Seng. Todd Schermerhorn will continue in his role as Chair of the Audit and Compliance Committee, with Mr Kozy remaining as Chair of the overall Board.